App-Quantinova.ai

The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax

Marta M. Szmyra - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

methionine

Assay Development and Small Molecule Screens for Inhibitors of an RNA Binding Protein Implicated in Hematologic Malignancies

Sean M. Post - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Venetoclax

HZ-R061, a Selective STAT3 Degrader with Activity in Preclinical Model of Hematologic Malignances

Yizhe WU - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ruxolitinib phosphate

Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma

Kim Anh Giang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identification of a Novel Nucleoside Prodrug with Preferential Activity in Lymphoma and Leukemia Subtypes

Marissa L Calbert - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Decitabine

Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling

Laura Nanni - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

Calculation of Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma Using a Deep Learning-Aided Automated Method

Juan Pablo Alderuccio - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

CD72 Is a Pan-Tumor Antigen Associated with Childhood Acute Leukemia

Barbara Buldini - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Efaproxiral

An Ex-Vivo Combination Drug Sensitivity Platform for Predicting Sensitivity to FLT3 Inhibitor-Based Combination in Acute Myeloid Leukemia

Noor Rashidha Binte Meera Sahib - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

gilteritinib

High-Efficiency Multi-Drug Functional Profiling in a Microfluidic Device Towards Personalized Predictions in Pediatric Leukemia

Evelyn Kendall Williams - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Daunorubicin

Prevalence of Pathogenic Germline Mutations in Solid Tumor Predisposition Genes Detected By Tumor-Normal Whole Exome Sequencing Analysis Among Adults with Hematologic Malignancies

Hussam Al-Kateb - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Causal AI in silico Patient Model Identifies Minichromosome Maintenance (MCM) Family Genes As Novel Predictors for Overall Survival in Multiple Myeloma

Daniel D Vagie - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

High Throughput Epigenomic Mapping of Hematopoietic Stem and Progenitor Cells Using Low Cell Input Acoustic Enhanced Immunoprecipitation

Besmira Alija - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Hironori Arai - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fuldazin

Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Imogen R Caldwell - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Developing a Cancer-Associated Thrombosis Clinic: Two-Year Experience

Brandon Bungo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Solid malignancies

N/A

Classical Hematology Referrals at an NCI-Designated Cancer Center: Lessons Learned

Chase West - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Solid malignancies

N/A

Reference Intervals for the Neutrophil to Lymphocyte Ratio (NLR) in the Elderly: Results from the Prospective Seniorlab Study

Lorenz Risch - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cost to Treat Newly Diagnosed Patients with Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Analysis

Anem Waheed - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Eculizumab

Filters

41730 Abstracts